医学
化疗
转移性尿路上皮癌
内科学
肿瘤科
癌
泌尿科
癌症
尿路上皮癌
膀胱癌
作者
Yohann Loriot,Nobuaki Matsubara,Se Hoon Park,Robert Huddart,Earle F. Burgess,Nadine Houédé,Séverine Banek,Valentina Guadalupi,Ja Hyeon Ku,Begoña P. Valderrama,Ben Tran,Spyros Triantos,Yin Kean,Sydney Akapame,Kris Deprince,Sutapa Mukhopadhyay,Nicole L. Stone,Arlene O. Siefker‐Radtke
标识
DOI:10.1056/nejmoa2308849
摘要
Erdafitinib therapy resulted in significantly longer overall survival than chemotherapy among patients with metastatic urothelial carcinoma and FGFR alterations after previous anti-PD-1 or anti-PD-L1 treatment. (Funded by Janssen Research and Development; THOR ClinicalTrials.gov number, NCT03390504.).
科研通智能强力驱动
Strongly Powered by AbleSci AI